ClinicalTrials.gg
CompletedNCT00755417Updated Mar 7, 2012Results posted

Study of Gabapentin Extended Release (G-ER) in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women

A Phase 3 interventional study of Gabapentin Extended-Release (G-ER) 1200 mg and Gabapentin Extended-Release (G-ER) 1800 mg in Hot Flashes, sponsored by Depomed. Completed at 45 sites in United States. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2012-03-07.

Sponsored by Depomed · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
541
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing gabapentin in Hot Flashes — none open to participants now, none under way, none of them phase 3. Gabapentin · Hot Flashes.

Enrollment
3rd of 10
541 · median 160
Started
2008
with 1 other
Phase 3
6 of 11
none open now
Registered
6th of 11
by date
Lead sponsor
4 of 11
Depomed

Among the 11 studies testing gabapentin in Hot Flashes, this one is the 3rd largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2008, is one of 6 in phase 3, and was the 6th registered.

Hot Flashes

339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.

Browse Hot Flashes studies →

Open to participants now

None of the 11 studies testing gabapentin in Hot Flashes is open now. The open studies under Hot Flashes, anywhere →

Where they have run

About gabapentin

Gabapentin: first FDA approval 1993 (NEURONTIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 36 Hot Flashes studies recruiting now, 13 (36%) set no upper age limit and 21 (58%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing gabapentin in Hot Flashes as a file.
02

Study summary

Depomed's Gabapentin Extended Release (G-ER) is an investigational, extended release formulation of gabapentin that is being studied for the treatment of hot flashes in postmenopausal women.

Read the detailed description

The primary study objective is to assess the efficacy of G-ER dosed in either of the following regimens:

  • G-ER 1200 mg daily (single evening dose)
  • G-ER 1800 mg daily (dosed asymmetrically; 600 mg in AM/1200 mg in PM) compared to placebo in reducing the average daily frequency and severity score of moderate to severe hot flashes in postmenopausal women after 4 weeks and 12 weeks of treatment with a stable dose, compared with the baseline week.
03

Conditions studied

  • Hot Flashes

Browse trials for

Keywords

  • Hot flashes
  • Hot flushes
  • Postmenopausal symptoms
  • Vasomotor symptoms
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. women aged 18 to 70 years experiencing ≥7 moderate to severe hot flashes per day (or ≥50 per week) accompanied by sweating during previous 30 days or longer.
  2. Had amenorrhea for ≥12 months, amenorrhea for 6 to 12 months with serum follicle-stimulating hormone (FSH) levels >40 mIU/mL, or was ≥6 weeks postsurgical bilateral oophorectomy with or without hysterectomy.
  3. Willing to discontinue the following: vaginal hormonal products; transdermal or oral estrogen or estrogen/progestin combination; intrauterine progestin; progestin implants; injectable estrogen; topical progesterone cream.
  4. Had to have daily average of ≥7 moderate to severe hot flashes and had to complete ≥4 days of diary entries during baseline week to be randomized.
  5. If treated with antidepressants, could not have had any changes in drug doses during past month.

Other Inclusions apply.

Exclusion criteria

Exclusion Criteria:

  1. Patient treated with a gonadotrophin releasing hormone agonist, anti-estrogens, or aromatase inhibitors within 2 months prior to study entry.
  2. Patient treated with estrogen pellets or progestin injectable drugs within 6 months prior to study entry.
  3. Patient experience only nighttime hot flashes or worked night shifts on a regular basis.
  4. Patient was concurrently treated with gabapentin for other indications. If patient was using gabapentin for treatment of hot flashes, she could be screened after a 7-day provided hot flashes returned.
  5. Patient had previously experienced dose-limiting adverse events that prevented titration of gabapentin to an effective dose.
  6. Patient had a to gabapentin.
  7. Patient was in an state.
  8. Patient had a other than basal cell carcinoma within 2 years prior to study entry.
  9. Patient had gastric reduction surgery, severe chronic diarrhea, chronic constipation, uncontrolled irritable bowel syndrome, uncontrolled inflammatory bowel disease, or unexplained weight loss.
  10. Patient had abnormal chemistry or hematology results, or calculated \<60 mL/min.
  11. Patient had history of substance abuse within year prior to study entry.
  12. Patient was concurrently taking morphine.
  13. Patient had history of chronic or C, hepatitis within 3 months prior to study entry, or history of .

Other Exclusions apply.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
541 participants (actual)

Study arms

  • Experimental
    G-ER 1200 mg

    Gabapentin extended-release (G-ER) 1200 mg

    Drug: Gabapentin Extended-Release (G-ER) 1200 mg

  • Experimental
    G-ER 1800 mg

    Gabapentin extended-release (G-ER) 1800 mg

    Drug: Gabapentin Extended-Release (G-ER) 1800 mg

  • Placebo comparator
    Sugar Pill

    Placebo 1200 mg or 1800 mg

    Drug: Placebo

Interventions

  • G-ER 1200 mg daily dosage given as two 600-mg tablets.

    Also known as: Gabapentin

  • G-ER 1800 mg daily dosage given as one 600-mg tablet in the morning and two 600-mg tablets in the evening.

    Also known as: Gabapentin

  • DrugPlacebo

    Matching placebo dosages of 1200 mg daily (two 600-mg tablets) and 1800 mg daily (one 600-mg tablet in the morning and two 600-mg tablets in the evening).

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Average Daily Frequency of Hot Flashes After 4 Weeks of Treatment With Daily Doses of G-ER 1200 mg or G-ER 1800 mg Compared to Placebo

    Change from baseline in average daily frequency of moderate to severe hot flashes after 4 weeks of treatment with stable daily doses of G-ER 1200 mg or G-ER 1800 mg compared with placebo, using last observation carried forward (LOCF) method of imputation for missing data in intent-to-treat (ITT) population.

    Time frame: From baseline to 4 weeks

  2. Change From Baseline in Average Daily Frequency of Hot Flashes After 12 Weeks of Treatment With Daily Doses of G-ER 1200 mg or G-ER 1800 mg Compared to Placebo

    Change from baseline in average daily frequency of moderate to severe hot flashes after 12 weeks of treatment with stable daily doses of G-ER 1200 mg or G-ER 1800 mg compared with placebo, using last observation carried forward (LOCF) method of imputation for missing data in intent-to-treat (ITT) population.

    Time frame: Form baseline to 12 weeks

  3. Change From Baseline in Average Daily Severity Score of Hot Flashes After 4 Weeks of Treatment With Daily Doses of G-ER 1200 mg or G-ER 1800 mg Compared to Placebo

    Change from baseline in average daily severity score of moderate to severe hot flashes after 4 weeks of treatment with stable daily doses of G-ER 1200 mg or G-ER 1800 mg compared with placebo, using last observation carried forward (LOCF) method of imputation for missing data in intent-to-treat (ITT) population. Severity score is on a 3-point scale where 1=Mild, 2=Moderate, and 3=Severe.

    Time frame: From baseline to 4 weeks

  4. Change From Baseline in Average Daily Severity Score of Hot Flashes After 12 Weeks of Treatment With Daily Doses of G-ER 1200 mg or G-ER 1800 mg Compared to Placebo

    Change from baseline in average daily severity score of moderate to severe hot flashes after 12 weeks of treatment with stable daily doses of G-ER 1200 mg or G-ER 1800 mg compared with placebo, using last observation carried forward (LOCF) method of imputation for missing data in intent-to-treat (ITT) population. Severity score is on a 3-point scale were 1=Mild, 2=Moderate, and 3=Severe.

    Time frame: From baseline to 12 weeks

07

Results

Posted Mar 7, 2012

Participant flow

Participant flow — Overall Study
MilestoneG-ER 1200 mgG-ER 1800 mgSugar Pill
Started174181177
Completed112126135
Not completed625542
Withdrew: Adverse event28207
Withdrew: Lack of efficacy849
Withdrew: Protocol violation211
Withdrew: Lost to follow-up301
Withdrew: Withdrawal by subject121212
Withdrew: Not specified or missing data91812

Outcome measures

PrimaryChange From Baseline in Average Daily Frequency of Hot Flashes After 4 Weeks of Treatment With Daily Doses of G-ER 1200 mg or G-ER 1800 mg Compared to Placebo

Change from baseline in average daily frequency of moderate to severe hot flashes after 4 weeks of treatment with stable daily doses of G-ER 1200 mg or G-ER 1800 mg compared with placebo, using last observation carried forward (LOCF) method of imputation for missing data in intent-to-treat (ITT) population.

Time frame:
From baseline to 4 weeks
Reported as:
Least squares mean · Moderate or severe hot flashes
Change From Baseline in Average Daily Frequency of Hot Flashes After 4 Weeks of Treatment With Daily Doses of G-ER 1200 mg or G-ER 1800 mg Compared to Placebo
Moderate or severe hot flashesG-ER 1200 mgG-ER 1800 mgSugar Pill
Change From Baseline in Average Daily Frequency of Hot Flashes After 4 Weeks of Treatment With Daily Doses of G-ER 1200 mg or G-ER 1800 mg Compared to Placebo-6.8 (-7.37 to -6.13)-7.3 (-7.89 to -6.71)-5.8 (-6.41 to -5.18)
Statistical analysis
  • G-ER 1200 mg vs Sugar Pill · ANCOVA · p = 0.0117 (Based on F test of type III analysis for pairwise comparison at 0.025 level.) · Mean difference (final values): -0.96 · 97.5% CI -1.81 to -0.11Included treatment and center factors and baseline value as a covariate, tested at the pairwise 0.025 level.
  • G-ER 1800 mg vs Sugar Pill · ANCOVA · p = <0.0001 (Based on F test of type III analysis) · Mean difference (final values): -1.51 · 97.5% CI -2.35 to -0.66Included treatment and center factors and baseline value as a covariate, tested at the pairwise 0.025 level.
PrimaryChange From Baseline in Average Daily Frequency of Hot Flashes After 12 Weeks of Treatment With Daily Doses of G-ER 1200 mg or G-ER 1800 mg Compared to Placebo

Change from baseline in average daily frequency of moderate to severe hot flashes after 12 weeks of treatment with stable daily doses of G-ER 1200 mg or G-ER 1800 mg compared with placebo, using last observation carried forward (LOCF) method of imputation for missing data in intent-to-treat (ITT) population.

Time frame:
Form baseline to 12 weeks
Reported as:
Least squares mean · Moderate or severe hot flashes
Change From Baseline in Average Daily Frequency of Hot Flashes After 12 Weeks of Treatment With Daily Doses of G-ER 1200 mg or G-ER 1800 mg Compared to Placebo
Moderate or severe hot flashesG-ER 1200 mgG-ER 1800 mgSugar Pill
Change From Baseline in Average Daily Frequency of Hot Flashes After 12 Weeks of Treatment With Daily Doses of G-ER 1200 mg or G-ER 1800 mg Compared to Placebo-7.4 (-8.10 to -6.73)-7.4 (-8.04 to -6.74)-6.9 (-7.53 to -6.18)
Statistical analysis
  • G-ER 1200 mg vs Sugar Pill · ANCOVA · p = 0.1830 (Based on F test of type III analysis.) · Mean difference (final values): -0.56 · 97.5% CI -1.49 to 0.38Included treatment and center factors and baseline value as a covariate, tested at the pairwise 0.025 level.
  • G-ER 1800 mg vs Sugar Pill · ANCOVA · p = 0.1975 (Based on F test of type III analysis.) · Mean difference (final values): -0.53 · 97.5% CI -1.46 to 0.40Included treatment and center factors and baseline value as a covariate, tested at the pairwise 0.025 level.
PrimaryChange From Baseline in Average Daily Severity Score of Hot Flashes After 4 Weeks of Treatment With Daily Doses of G-ER 1200 mg or G-ER 1800 mg Compared to Placebo

Change from baseline in average daily severity score of moderate to severe hot flashes after 4 weeks of treatment with stable daily doses of G-ER 1200 mg or G-ER 1800 mg compared with placebo, using last observation carried forward (LOCF) method of imputation for missing data in intent-to-treat (ITT) population. Severity score is on a 3-point scale where 1=Mild, 2=Moderate, and 3=Severe.

Time frame:
From baseline to 4 weeks
Reported as:
Least squares mean · Score on a numerical scale
Change From Baseline in Average Daily Severity Score of Hot Flashes After 4 Weeks of Treatment With Daily Doses of G-ER 1200 mg or G-ER 1800 mg Compared to Placebo
Score on a numerical scaleG-ER 1200 mgG-ER 1800 mgSugar Pill
Change From Baseline in Average Daily Severity Score of Hot Flashes After 4 Weeks of Treatment With Daily Doses of G-ER 1200 mg or G-ER 1800 mg Compared to Placebo-0.5 (-0.68 to -0.41)-0.6 (-0.74 to -0.48)-0.3 (-0.42 to -0.15)
Statistical analysis
  • G-ER 1200 mg vs Sugar Pill · ANCOVA · p = 0.0016 (Based on F test of type III analysis.) · Mean difference (final values): -0.26 · 97.5% CI -0.44 to -0.08Included treatment and center factors and baseline value as a covariate, tested at the pairwise 0.025 level.
  • G-ER 1800 mg vs Sugar Pill · ANCOVA · p = <0.0001 (Based on the F test of type III analysis.) · Mean difference (final values): -0.32 · 97.5% CI -0.51 to -0.14Included treatment and center factors and baseline value as a covariate, tested at the pairwise 0.025 level.
PrimaryChange From Baseline in Average Daily Severity Score of Hot Flashes After 12 Weeks of Treatment With Daily Doses of G-ER 1200 mg or G-ER 1800 mg Compared to Placebo

Change from baseline in average daily severity score of moderate to severe hot flashes after 12 weeks of treatment with stable daily doses of G-ER 1200 mg or G-ER 1800 mg compared with placebo, using last observation carried forward (LOCF) method of imputation for missing data in intent-to-treat (ITT) population. Severity score is on a 3-point scale were 1=Mild, 2=Moderate, and 3=Severe.

Time frame:
From baseline to 12 weeks
Reported as:
Least squares mean · Score on a numerical scale
Change From Baseline in Average Daily Severity Score of Hot Flashes After 12 Weeks of Treatment With Daily Doses of G-ER 1200 mg or G-ER 1800 mg Compared to Placebo
Score on a numerical scaleG-ER 1200 mgG-ER 1800 mgSugar Pill
Change From Baseline in Average Daily Severity Score of Hot Flashes After 12 Weeks of Treatment With Daily Doses of G-ER 1200 mg or G-ER 1800 mg Compared to Placebo-0.7 (-0.91 to -0.58)-0.7 (-0.90 to -0.59)-0.5 (-0.71 to -0.38)
Statistical analysis
  • G-ER 1200 mg vs Sugar Pill · ANCOVA · p = 0.0433 (Based on the F test of type III analysis.) · Mean difference (final values): -0.20 · 97.5% CI -0.43 to 0.02Included treatment and center factors and baseline value as a covariate, tested at the pairwise 0.025 level.
  • G-ER 1800 mg vs Sugar Pill · ANCOVA · p = 0.0468 (Based on the F test of type III analysis.) · Mean difference (final values): -0.20 · 97.5% CI -0.42 to 0.03Included treatment and center factors and baseline value as a covariate, tested at the pairwise 0.025 level.

Adverse events

Collected over Total of 26 weeks: from randomization through 1 week after study completion (week 25).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
G-ER 1200 mg—2/174 (1.1%)148/174 (85.1%)
G-ER 1800 mg—6/181 (3.3%)167/181 (92.3%)
Sugar Pill—4/177 (2.3%)65/177 (36.7%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventG-ER 1200 mgG-ER 1800 mgSugar Pill
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1741/1810/177
Gastroesophageal reflux disease exacerbationGastrointestinal disorders1/1740/1810/177
Abdominal herniaGastrointestinal disorders0/1740/1811/177
Cerebrovascular disorderNervous system disorders0/1740/1811/177
Chest painGeneral disorders0/1740/1811/177
Coronary artery diseaseCardiac disorders0/1740/1811/177
Malignant lung neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1741/1810/177
Nerve compressionNervous system disorders0/1741/1810/177
PneumothoraxRespiratory, thoracic and mediastinal disorders0/1741/1810/177
Rib fractureInjury, poisoning and procedural complications0/1741/1810/177
Most frequent other events
Showing 10 of 11
Most frequent other events
EventG-ER 1200 mgG-ER 1800 mgSugar Pill
DizzinessNervous system disorders41/17435/1815/177
SomnolenceNervous system disorders23/17435/1814/177
HeadacheNervous system disorders15/17417/18110/177
NauseaGastrointestinal disorders12/17416/1817/177
NasopharyngitisInfections and infestations14/17411/1817/177
VomitingGastrointestinal disorders3/17413/1814/177
FlatulenceGastrointestinal disorders11/1747/1812/177
Upper respiratory tract infectionInfections and infestations11/17410/18110/177
FatigueGeneral disorders9/1749/1813/177
Back painMusculoskeletal and connective tissue disorders4/1745/1819/177

Baseline characteristics

Age Continuous
Age Continuous(Years)G-ER 1200 mgG-ER 1800 mgSugar PillTotal
Mean52.9 ± 5.352.9 ± 6.553.0 ± 6.652.9 ± 6.2
Age, Customized
Age, Customized(Participants)G-ER 1200 mgG-ER 1800 mgSugar PillTotal
<65 years170176170516
>=65 years45716
Sex: Female, Male
Sex: Female, Male(Participants)G-ER 1200 mgG-ER 1800 mgSugar PillTotal
Female174181177532
Male0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)G-ER 1200 mgG-ER 1800 mgSugar PillTotal
White121125111357
Black393750126
Asian1113
Hispanic12131237
Other1539
Number of hot flashes in 24-hour period
Number of hot flashes in 24-hour period(Hot flashes)G-ER 1200 mgG-ER 1800 mgSugar PillTotal
Moderate hot flashes6.1 ± 4.56.2 ± 5.76.3 ± 5.66.2 ± 5.3
Severe hot flashes6.4 ± 4.67.4 ± 5.87.1 ± 5.97.0 ± 5.5
08

Study locations

45 sites
  • Birmingham, Alabama, United States
  • Montgomery, Alabama, United States
  • Tempe, Arizona, United States
  • Tucson, Arizona, United States
  • Berkely, California, United States
  • La Mesa, California, United States
  • San Diego, California, United States
  • Santa Rosa, California, United States
  • Denver, Colorado, United States
  • Lakewood, Colorado, United States
  • Waterbury, Connecticut, United States
  • Washington, District of Columbia, United States
  • Clearwater, Florida, United States
  • Jacksonville, Florida, United States
  • New Port Richey, Florida, United States
  • Orlando, Florida, United States
  • St. Petersburg, Florida, United States
  • Tampa, Florida, United States
  • Atlanta, Georgia, United States
  • Sandy Springs, Georgia, United States
  • Savannah, Georgia, United States
  • Chicago, Illinois, United States
  • Madisonville, Kentucky, United States
  • Fall River, Massachusetts, United States
  • Edina, Minnesota, United States
  • St. Louis, Missouri, United States
  • Billings, Montana, United States
  • Las Vegas, Nevada, United States
  • Moorestown, New Jersey, United States
  • Raleigh, North Carolina, United States
  • Wilmington, North Carolina, United States
  • Fargo, North Dakota, United States
  • Columbus, Ohio, United States
  • Pittsburgh, Pennsylvania, United States
  • West Reading, Pennsylvania, United States
  • Columbia, South Carolina, United States
  • Hilton Head Island, South Carolina, United States
  • Nashville, Tennessee, United States
  • Dallas, Texas, United States
  • Houston, Texas, United States
  • San Antonio, Texas, United States
  • Salt Lake City, Utah, United States
  • Bellevue, Washington, United States
  • Renton, Washington, United States
  • Spokane, Washington, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2008, a primary completion of Aug 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2012, 2 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2008
First posted
Sep 19, 2008
Start
Sep 2008
Primary completionActual
Aug 2009
CompletionActual
Oct 2009
Results first posted
Mar 7, 2012
Last update
Mar 7, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00755417
Lead sponsor
Depomed
Responsible party
Sponsor
First posted
Sep 19, 2008
Start date
Sep 2008
Primary completion
Aug 2009
Completion
Oct 2009
Results posted
Mar 7, 2012
Last update
Mar 7, 2012

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gabapentin

Start the discussion